Skip to main content
NGNE logo

NGNE · Neurogene Inc.

Track NGNE — free
$22.15 -0.78 (-3.40%) At close · Nov 20
Market Cap
$458.53M
Shares
20.70M
Volume · Nov 20 178.27K Avg daily vol (3M) 308.44K

Price & Indicators

 

Key stats

Close
$22.15
Fri 20 Nov
Open
$22.27
Fri 20 Nov
Average volume, 30 days
316K
shares a session
Short interest
5.7M
27.5% of shares · 17.0 days to cover
Day range
$22.03$22.90
Open $22.27 Close $22.15
52-week closing range
$16.37$42.84
Close $22.15 48.3% under the high
Short volume, last session
70%
Last earnings
Aug 11, 2025
Latest filing
10-Q · Nov 9
Price history
Jan 2020 to Nov 2026

Latest documents

2026
Nov 11
Investor event
NGN-401 dosing complete, data due second half of 27

NeuroGene completed dosing in the NGN-401 pivotal study and expects data in the second half of 27. It had about $360 million in cash and equivalents at quarter-end, funding operations into the first quarter of 29.

4 source passages
NGN401 completed dosing of our pivotal study, and I know we'll have lots of questions on that, but we completed dosing. data coming out in the second half of 27 ended the quarter with about $360 million in cash and equivalents, and that takes us into the first quarter of 29 Really happy to be here. So again, Rachel McMinn, founder and CEO of NeuroGene. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
NGN-401 dosing complete; runway projected into first quarter of 2029

Neurogene Inc. completed dosing 25 participants in the Embolden registrational trial for NGN-401, expects topline results in the second half of 2027, and expects cash, cash equivalents and investments to fund operations into the first quarter of 2029.

Net loss $29.02M Diluted EPS -$1.05
Read from the MD&A section
4 source passages
In this section, references to “we,” “our,” “us,” and “the Company” refer to post-merger Neurogene Inc. and our wholly owned subsidiary incorporated in the state of Nevada, also named Neurogene Inc. (“Neurogene OpCo”), unless otherwise indicated. We have completed dosing of 25 participants in our ongoing registrational trial of NGN-401, EmboldenTM, a single-arm, open-label, baseline-controlled trial evaluating the 1E15 vg dose of NGN-401 gene therapy in females with Rett syndrome. Topline results are expected in the second half of 2027. Following the completion of our July 2026 public offering, we believe our existing cash, cash equivalents and investments will be sufficient to fund our operations into the first quarter of 2029. Open the document at this passage
Nov 9
Current report 8-K
NGN-401 2H 2027 readout; runway into first quarter 2029

Neurogene reported $359.7 million in cash and investments as of September 30, 2026, funding operations into first quarter 2029. NGN-401 Embolden topline data are expected in 2H 2027, with PPQ runs expected to complete by year-end 2026.

Financial results
5 source passages
On November 9, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2026. Topline data from Embolden™ registrational trial anticipated in 2H 2027 NGN-401 is an investigational AAV9 gene therapy in late-stage clinical development as a potential best-in-class, one-time treatment for Rett syndrome. Cash, Cash Equivalents and Short-Term Investments: Cash, cash equivalents and short-term investments as of September 30, 2026 were $359.7 million and are expected to fund planned operations into the first quarter of 2029. Complete BLA-enabling PPQ runs by year-end 2026 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$119.18M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-21.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$359.71M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+30.8%
Year over year · more shares
Price change (1Y)
+8.6%
Trailing year
Short interest
27.5%
Latest settlement · 17.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross Death cross
Price vs 200-day avg −22%
below
Price vs 50-day avg −17%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 22%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −6%
trailing
6-month return −15%
trailing
YTD return +8%
this year
Relative strength −6%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $27 › 200d $28 — 200d above 50d
Institutional flow Accumulating
+19% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
27.47% of shares out · ▲ +11.6% MoM · 17.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
133 holders — near 3-yr high, broad support
Squeeze score 80
high risk · 0–100
Fundamentals
Weak
Revenue growth −100%
Y/Y
EPS growth +1%
Y/Y
Free cash flow $-78.4M
Balance sheet $103.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 75%
annualized · 1-yr
Max drawdown −50%
past year
ATR 8.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−22% Bearish
Price vs 50-day avg
−17% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
22% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) Death cross
50d $27 › 200d $28 — 200d above 50d
Institutional flow Accumulating
+19% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
27.47% of shares out · ▲ +11.6% MoM · 17.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
133 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $16 Now $22 · 22% Range high $43
vs 200-day avg -22% vs 50-day avg -17% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Average milestones per participant 1.9 at 6 months —
Average milestones per participant at 12 months 3.7 12 months —
Average milestones per participant at 6 months 0.9 6 months —
Embolden Composite responder rate (CGI-I ≤3 + ≥1 milestone) 80% as of data cutoff date of June 16, 2026 —
Embolden milestones gained across 10 Phase 1/2 participants 21 as of data cutoff date of June 16, 2026 —
Mean RSGMS total-score gain 5.2 Post treatment (N=10) —
Mean RSHFS total-score gain per hand 1.8 Post treatment (N=10; 1-2.5 years) —
Median time to first response 2 median time observed post treatment —
Participants gained ≥1 developmental milestone at ≥12 months 100% at ≥12 months —
Phase 1/2 participants gaining ≥1 developmental milestone and improving on CGI-I 100% at ≥12 months —
Phase 1/2 participants gaining ≥2 developmental milestones 7 data cutoff date of June 16, 2026 —
Response rate (Phase 1/2 responders at 12 months) 80% Phase 1/2 at 12 months —
Total developmental milestones gained 47 as of data cutoff date of June 16, 2026 —
Total NGN-401 participants dosed in Embolden 25 as of data cutoff date of June 16, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NGNE
Neurogene Inc.
this stock
$458.53M +7.5% -100.0% — 27.5%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
133
% held
115.9%
Net QoQ
+6.7M sh
Top holder
JENNISON ASSOCIATES LLC
Held Float
View
Held by Funds
Fund positions
135
View
Short & Settlement
Short Interest Rising
Shares short
5.7M
Days to cover
17.0d
Change
+592.4K sh
View
Short Volume
Short vol %
70%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
6
Value
$173
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
43.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-90.4M
EPS diluted
$-4.24
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 11, 2026
This year
19

NeuroGene completed dosing in the NGN-401 pivotal study and expects data in the second half of 27. It had about $360 million in cash and equivalents at quarter-end, funding operations into the first quarter of 29.

View
Proposed Sales
Value
$151.6K
Shares
6.8K
Filed
Mar 13, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
Neurogene Reports Third Quarter 2…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
NGNE -7.4% -5.9% -15.3% -19.6% +7.5%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +1.1% +3.3% -6.1% -10.9% +6.4%
Key facts CIK 1404644 CUSIP 64135M105 13F (30d) 128 filings 122 filers Visit website Investor relations